| Blockade of microglial Kv1. 3 potassium channels by the peptide HsTX1 [R14A] attenuates lipopolysaccharide-mediated neuroinflammation JA Nicolazzo, Y Pan, I Di Stefano, KHC Choy, SB Reddiar, YL Low, ... Journal of Pharmaceutical Sciences 111 (3), 638-647, 2022 | 14 | 2022 |
| A Fluorescent Peptide Toxin for Selective Visualization of the Voltage-Gated Potassium Channel KV1.3 DCC Wai, MU Naseem, G Mocsár, S Babu Reddiar, Y Pan, A Csoti, ... Bioconjugate Chemistry 33 (11), 2197-2212, 2022 | 8 | 2022 |
| Lipopolysaccharide influences the plasma and brain pharmacokinetics of subcutaneously-administered HsTX1 [R14A], a Kv1. 3-blocking peptide SB Reddiar, L Jin, DCC Wai, A Csoti, G Panyi, RS Norton, JA Nicolazzo Toxicon 195, 29-36, 2021 | 8 | 2021 |
| A biodistribution study of the radiolabeled kv1. 3-blocking peptide DOTA-HsTX1 [r14a] demonstrates brain uptake in a mouse model of neuroinflammation SB Reddiar, M De Veer, BM Paterson, T Sepehrizadeh, DCC Wai, A Csoti, ... Molecular Pharmaceutics 20 (1), 255-266, 2022 | 6 | 2022 |
| Assessing the cellular toxicity of peptide inhibitors of intracellular protein-protein interactions by microinjection SB Reddiar, H Al-Wassiti, CW Pouton, CJ Nowell, MA Matthews, ... Bioorganic & Medicinal Chemistry 29, 115906, 2021 | 4 | 2021 |
| Intestinal Lymphatic Biology, Drug Delivery, and Therapeutics: Current Status and Future Directions SB Reddiar, Y Xie, M Abdallah, S Han, L Hu, OM Feeney, G Gracia, ... Pharmacological Reviews 76 (6), 1326-1398, 2024 | 1 | 2024 |
| Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats SB Reddiar, M Abdallah, IK Styles, OO Müllertz, NL Trevaskis European Journal of Pharmaceutics and Biopharmaceutics 200, 114339, 2024 | 1 | 2024 |
| Lymphatic uptake of a highly lipophilic protease inhibitor prodrug from a lipid-based formulation is limited by instability in the intestine Y Xie, Z Lu, IK Styles, SB Reddiar, ARJ Phillips, JA Windsor, CJH Porter, ... Journal of Pharmaceutical Sciences, 2024 | | 2024 |
| Brain Delivery and Biodistribution of the Kv1. 3 Channel Blocker, HsTX1 [R14A], a Potential Therapeutic for Neuroinflammatory Diseases SB REDDIAR Monash University, 0 | | |